1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. Wee1

Wee1

Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission yeast Schizosaccharomyces pombe (S. pombe). Wee1 has amolecular mass of 96 kDa and it is a key regulator of cell cycle progression. Wee1 influences cell size by inhibiting the entry into mitosis, through inhibiting Cdk1. Wee1 has homologues in many other organisms, including mammals. Wee1 inhibits Cdk1 by phosphorylating it on two different sites, Tyr15 and Thr14. Cdk1 is crucial for the cyclin-dependent passage of the various cell cycle checkpoints. At least three checkpoints exist for which the inhibition of Cdk1 by Wee1 is important: G2/M checkpoint, Cell size checkpoint, DNA damage checkpoint. Wee1 is shown to phosphorylate histone H2B at tyrosine 37 residue which regulates global expression of histones.

Wee1 Related Products (24):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10993
    Adavosertib
    Inhibitor 99.97%
    Adavosertib (AZD-1775; MK-1775) is a potent Wee1 inhibitor with an IC50 of 5.2 nM.
    Adavosertib
  • HY-145817A
    RP-6306
    Inhibitor 99.65%
    RP-6306 ((S)-RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. RP-6306 shows a high degree of selectivity over other kinases in cellular binding assays. RP-6306 shows anticancer effects.
    RP-6306
  • HY-13925
    PD0166285
    Inhibitor 99.46%
    PD0166285, a substrate of P-gp, is a WEE1 inhibitor and a weak Myt1 inhibitor with IC50 values of 24 and 72 nM, respectively. PD0166285 exhibits an IC50 of 3.433 μM for Chk1.
    PD0166285
  • HY-18961
    PD 407824
    Inhibitor 98.02%
    PD 407824 is a checkpoint kinase Chk1 and WEE1 inhibitor with IC50s of 47 and 97 nM, respectively. PD 407824 is a chemical BMP sensitizer and increases the sensitivity of cells to sub-threshold amounts of BMP4.
    PD 407824
  • HY-147054
    WEE1-IN-5
    Inhibitor 99.90%
    WEE1-IN-5 is a potent WEE1 inhibitor with an IC50 value of 0.8 nM. WEE1-IN-5 inhibits phospho-CDC2. WEE1-IN-5 abrogates the G2 check point, increasing sensitivity to DNA damaging agents in cancer cells. WEE1-IN-5 can be used for researching anticancer.
    WEE1-IN-5
  • HY-160530
    WEE1-IN-6
    Inhibitor
    WEE1-IN-6 (compound 110) is a orally active WEE1 inhibitor with an DC50 value of ≦ 100 nM. WEE1-IN-6 inhibits cell proliferation.
    WEE1-IN-6
  • HY-103029
    Bosutinib isomer
    Inhibitor
    Bosutinib isomer is a ligand or inhibitor with high binding affinity for both Wee1 and Wee2, with Kd values of 43.7 ± 10.0 and 4.7 ± 2.3 nM, respectively.
    Bosutinib isomer
  • HY-157443
    Myt1-IN-4
    Inhibitor
    Myt1-IN-4 (21) is an orally active and selective MYT1 inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity.
    Myt1-IN-4
  • HY-145817
    (Rac)-RP-6306
    Inhibitor 99.72%
    (Rac)-RP-6306 (compound 181) is a potent Myt1 inhibitor with an IC50 of <10 nM. (Rac)-RP-6306 (compound 181) has anticancer effects.
    (Rac)-RP-6306
  • HY-148062
    RSS0680
    98.03%
    RSS0680 (Example 22) is a bifunctional compound targeted protein degradation of kinases. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used for research of disease or disorder mediated by aberrant kinase activity.
    RSS0680
  • HY-148063
    DB0614
    98.80%
    DB0614 (Example 21) is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity.
    DB0614
  • HY-145817B
    (R)-RP-6306
    Inhibitor 99.87%
    (R)-RP-6306 can be used for the research of Myt1 mediated diseases and kinds of cancer for slowing the progression of cancer. (R)-RP-6306 (IC50=1360nM) is less active than (S)-RP-6306 (IC50<10nM).
    (R)-RP-6306
  • HY-145664
    Myt1-IN-1
    Inhibitor 98.99%
    Myt1-IN-1 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-1 has anticancer effects (WO2021195782A1; compound 132).
    Myt1-IN-1
  • HY-138239
    WEE1-IN-3
    Inhibitor 98.64%
    WEE1-IN-3 is a potent Wee1 kinase inhibitor with an IC50 of <10 nM. WEE1-IN-3 has anticancer activities.
    WEE1-IN-3
  • HY-108343
    WEE1-IN-4
    Inhibitor 99.60%
    WEE1-IN-4 is a potent checkpoint Wee1 kinase inhibitor with an IC50 of 0.011 μM.
    WEE1-IN-4
  • HY-145666
    Myt1-IN-3
    Inhibitor 99.14%
    Myt1-IN-3 is a potent Myt1 inhibitor with an IC50s of <10 nM (WO2021195782 A1, compound 95).
    Myt1-IN-3
  • HY-133618
    Pomalidomide-C3-adavosertib
    Modulator 99.84%
    Pomalidomide-C3-adavosertib is a rapid and selective Wee1 degrader (IC50=3.58 nM). Pomalidomide-C3-adavosertib shows anti-cancer cell proliferation activity, and induces apoptosis.
    Pomalidomide-C3-adavosertib
  • HY-122113
    PD173952
    Inhibitor
    PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a Ki of 8.1 nM. PD173952 induces apoptosis.
    PD173952
  • HY-145665
    Myt1-IN-2
    Inhibitor
    Myt1-IN-2 is a potent Myt1 inhibitor with an IC50 of <10 nM. Myt1-IN-2 has anticancer effects (WO2021195782A1; compound 28).
    Myt1-IN-2
  • HY-143342
    LEB-03-144
    LEB-03-144 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through a C3 alkyl linker. LEB-03-144 shows significant WEE1 stabilization in HEP3B hepatoma cancer cells.
    LEB-03-144